

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP

Plot No. 19A, 2nd Floor,
Sector - 16A,
Noida - 201 301
Uttar Pradesh, India
T +91 120 485 5999
F +91 120 485 5902

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

Opinion

1. We have audited the accompanying standalone annual financial results ('the Statement') of Jubilant Ingrevia Limited ('the Company') for the year ended 31 March 2022, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) presents financial results in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations; and
 - (ii) gives a true and fair view in conformity with the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the year ended 31 March 2022.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune



Walker Chandiok & Co LLP is registered
with limited liability with identification
number AAC-2085 and has its registered
office at L-41 Connaught Circus, Outer
Circle, New Delhi, 110001, India

Walker Chandiook & Co LLP

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Responsibilities of Management and Those Charged with Governance for the Statement

4. This Statement has been prepared on the basis of the standalone annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/loss and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
5. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing, specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls;



Walker Chandiok & Co LLP

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management;
 - Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

11. We did not audit note 5 of the accompanying Statement of the Company for the year ended 31 March 2022, which represents supplementary information relating to the operations of the life science ingredients business for the period from 1 April 2020 to 31 January 2021, which has been prepared by the management of the Company and has not been subjected to an audit or a review by us. Our opinion is not modified in respect of this matter.
12. The Statement includes the standalone financial results for the quarter ended 31 March 2022, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us. Our opinion is not modified in respect of this matter.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm Registration No.: 001076N/N500013


Ashish Gupta

Partner

Membership No. 504662



UDIN: 22504662AJBYKS4038

Place: Noida

Date: 17 May 2022

Jubilant Ingrevia Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubil.com, Tel: +91-5924-267437

Statement of Standalone Audited Financial Results for the Quarter and Year ended 31 March 2022

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31 March	31 December	31 March	31 March	31 March
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
		2022	2021	2021	2022	2021
1	Revenue from operations					
	a) Sales/Income from operations	124769	125280	66377	483121	66377
	b) Other operating income	1419	344	516	2921	516
	Total revenue from operations	126188	125624	66893	486042	66893
2	Other income	664	930	245	2882	245
3	Total Income (1+2)	126852	126554	67138	488924	67138
4	Expenses					
	a) Cost of materials consumed	70016	75274	36346	279818	36346
	b) Purchases of stock-in-trade	2902	1848	1452	11455	1452
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	1706	(3656)	993	(9089)	993
	d) Employee benefits expense	7401	7964	4311	29241	4311
	e) Finance costs	989	862	945	4624	945
	f) Depreciation and amortisation expense	3033	2963	2135	12013	2135
	g) Other expenses:					
	- Power and fuel expense	14778	13401	5279	47268	5279
	- Others	13812	10908	8829	46047	8829
	Total expenses	114637	109564	60290	421377	60290
5	Profit before exceptional items and tax (3-4)	12215	16990	6848	67547	6848
6	Exceptional items	-	-	1294	-	1294
7	Profit before tax (5-6)	12215	16990	5554	67547	5554
8	Tax expense					
	- Current tax	2161	2952	971	11749	971
	- Deferred tax charge	2606	2334	724	10573	724
9	Net profit for the year/period (7-8)	7448	11704	3859	45225	3859
10	Other comprehensive income (OCI)					
	i) a) Items that will not be reclassified to profit or loss	197	(123)	(33)	(171)	(33)
	b) Income tax relating to items that will not be reclassified to profit or loss	(69)	44	12	60	12
	ii) a) Items that will be reclassified to profit or loss	-	-	-	-	-
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
11	Total comprehensive income for the year/period (9+10)	7576	11625	3838	45114	3838
12	Earnings per share of ₹ 1 each (not annualised for the quarters)					
	Basic (₹)	4.67	7.35	3.69	28.39	14.75
	Diluted (₹)	4.67	7.35	3.69	28.39	14.75
13	Paid-up equity share capital (face value per share ₹ 1)	1593	1593	1593	1593	1593
14	Reserves excluding revaluation reserves (other equity)				196712	155992
	See accompanying notes to the Standalone Audited Financial Results					

Jubilant Ingrevia Limited
Statement of Standalone Audited Assets and Liabilities

(₹ in Lakhs)

Sr. No.	Particulars	As at	As at
		31 March	31 March
		(Audited)	(Audited)
		2022	2021
A	ASSETS		
1.	Non-current assets		
	Property, plant and equipment	165235	164528
	Capital work-in-progress	16171	6291
	Intangible assets	294	471
	Intangible assets under development	496	191
	Right-of-use assets	7229	7684
	Financial assets		
	Investment in subsidiaries and associates	13919	13489
	Loans	50	53
	Other financial assets	1003	233
	Income-tax assets (net)	89	89
	Other non-current assets	2238	1466
	Total non-current assets	206724	194495
2.	Current assets		
	Inventories	76262	52062
	Financial assets		
	Trade receivables	58508	48028
	Cash and cash equivalents	2150	6569
	Other bank balances	292	1996
	Loans	41	49
	Other financial assets	6311	5050
	Other current assets	14925	15748
	Total current assets	158489	129502
	Total assets	365213	323997
B	EQUITY AND LIABILITIES		
1.	Equity		
	Equity share capital	1593	1593
	Other equity	196712	155992
	Total equity	198305	157585
2.	Liabilities		
	Non-current liabilities		
	Financial liabilities		
	Borrowings	29568	64683
	Lease liabilities	4087	4275
	Provisions	6495	6600
	Deferred tax liabilities (net)	13661	2788
	Total non-current liabilities	53811	78346
	Current liabilities		
	Financial liabilities		
	Borrowings	12906	8966
	Lease liabilities	296	248
	Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	2046	1796
	Total outstanding dues of creditors other than micro enterprises and small enterprises	77420	67686
	Other financial liabilities	7574	6941
	Other current liabilities	10559	1755
	Provisions	1660	1174
	Current tax liabilities (net)	636	-
	Total current liabilities	113097	88066
	Total equity and liabilities	365213	323997

Jubilant Ingrevia Limited
Note 1: Statement of Standalone Audited Cash Flows

(₹ in lakhs)

Particulars	Year Ended	
	31 March	31 March
	(Audited)	(Audited)
	2022	2021
A. Cash flows from operating activities		
Profit before tax	67547	5554
Adjustments:		
Depreciation and amortisation expense	12013	2135
Loss on sale/disposal/discard of property, plant and equipment (net)	823	-
Finance costs	4624	945
Share-based payment expense	145	-
Unrealised foreign exchange loss (net)	268	367
Interest income	(115)	(42)
Exceptional items	-	1294
	17758	4699
Operating cash flows before working capital changes	85305	10253
Increase in trade receivables, loans, other financial assets and other assets	(10835)	(4081)
Increase in inventories	(24200)	(1767)
Increase in trade payables, other financial liabilities, other liabilities and provisions	19522	7071
Cash generated from operations	69792	11476
Income-tax paid (net of refund)	(11112)	(1059)
Net cash generated from operating activities	58680	10417
B. Cash flows from investing activities		
Purchase of property, plant and equipment, intangible assets (including capital work-in-progress, intangible assets under development and capital advances)	(22463)	(2751)
Proceeds from sale of property, plant and equipment	258	4
Investment in subsidiaries and associates	(934)	(216)
Movement in other bank balances	936	(69)
Interest received	127	92
Net cash used in investing activities	(22076)	(2940)
C. Cash flows from financing activities		
Repayment of long-term borrowings	(44781)	(6219)
Payment of principal balances of lease liabilities	(292)	(30)
Proceeds from short-term borrowings (net)	12906	-
Proceeds from borrowings taken from subsidiary	2300	-
Repayment of borrowings to subsidiary	(1800)	-
Dividend paid	(4524)	-
Finance costs paid (including interest on lease liabilities)	(4832)	(771)
Net cash used in financing activities	(41023)	(7020)
Net (decrease)/increase in cash and cash equivalents (A+B+C)	(4419)	457
Add: cash and cash equivalents at the beginning of the year	6569	5
Add: cash and cash equivalents acquired pursuant to the Composite Scheme (refer note 4)	-	6107
Cash and cash equivalents at the end of the year	2150	6569

Jubilant Ingrevia Limited

Note 2: Standalone Audited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Year ended 31 March 2022

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31 March	31 December	31 March	31 March	31 March
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
		2022	2021	2021	2022	2021
1	Segment revenue					
	a. Speciality Chemicals	50131	43115	24980	168533	24980
	b. Nutrition & Health Solutions	19020	19853	11355	74342	11355
	c. Chemical Intermediates	67599	74944	36848	290734	36848
	Total	136750	137912	73183	533609	73183
	Less : Inter segment revenue	10562	12288	6290	47567	6290
	Total revenue from operations	126188	125624	66893	486042	66893
	a. Speciality Chemicals	43524	34514	19850	135373	19850
	b. Nutrition & Health Solutions	19020	19853	11355	74342	11355
	c. Chemical Intermediates	63644	71257	35688	276327	35688
	Total	126188	125624	66893	486042	66893
2	Segment results (profit before tax, exceptional items and interest from each segment)					
	a. Speciality Chemicals	6893	5913	2460	24359	2460
	b. Nutrition & Health Solutions	4162	4363	1766	13512	1766
	c. Chemical Intermediates	3119	8282	3805	37402	3805
	Total	14174	18558	8031	75273	8031
	Less: i. Interest (finance costs)	989	862	945	4624	945
	ii. Exceptional items and un-allocable expenditure (net of un-allocable income)	970	706	1532	3102	1532
	Profit before tax	12215	16990	5554	67547	5554
3	Segment assets					
	a. Speciality Chemicals	179382	158672	145360	179382	145360
	b. Nutrition & Health Solutions	41543	44998	36934	41543	36934
	c. Chemical Intermediates	123609	134608	115045	123609	115045
	d. Unallocable corporate assets	20679	22051	26658	20679	26658
	Total segment assets	365213	360329	323997	365213	323997
4	Segment liabilities					
	a. Speciality Chemicals	40654	24802	33690	40654	33690
	b. Nutrition & Health Solutions	19536	19626	8008	19536	8008
	c. Chemical Intermediates	48792	61400	47166	48792	47166
	d. Unallocable corporate liabilities	57926	59831	77548	57926	77548
	Total segment liabilities	166908	165659	166412	166908	166412

Jubilant Ingrevia Limited

Note 3: Additional disclosure as per Regulation 52 (4) and 54 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Standalone)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31 March	31 December	31 March	31 March	31 March
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
		2022	2021	2021##	2022	2021##
1	Debt service coverage ratio (in times)# <i>Definition: EBITDA/(finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts)</i> <i>{EBITDA: Profit before tax + depreciation and amortisation expense + finance costs + exceptional items}</i>	16.41	12.20	4.22	6.15	4.22
2	Interest service coverage ratio (in times) <i>Definition: EBITDA/finance costs</i>	16.41	24.14	10.51	18.20	10.51
3	Bad debts to account receivable ratio (%)# <i>Definition: Bad debts/average of opening and closing trade receivables</i> <i>{Bad debts: Impairment balance as per statements of profit and loss}</i>	-	0.20%	0.10%	0.25%	0.10%
4	Debtors turnover (in times)# <i>Definition: Revenue from operations/average of opening and closing trade receivables</i>	2.13	2.03	1.40	9.12	1.40
5	Inventory turnover (in times)# <i>Definition: Cost of goods sold/average of opening and closing inventories</i>	1.01	1.10	0.76	4.40	0.76
6	Operating margin (%) <i>Definition: Operating profit/revenue from operations</i> <i>{Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense including exceptional expense - other expenses}</i> <i>{Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress}</i>	9.94%	13.47%	9.35%	14.26%	9.35%
7	Net profit margin (%) <i>Definition: Net profit/total income</i>	5.87%	9.25%	5.75%	9.25%	5.75%
8	Paid-up debt capital (in ₹ Lakhs) <i>Definition: Secured Rated Listed Redeemable Non-Convertible Debentures (Gross of debt initiation cost)</i>	10000	10000	10000	10000	10000
9	Net worth (in ₹ Lakhs) <i>{Net worth: Equity share capital + other equity}</i>	198305	194670	157585	198305	157585
10	Debt equity ratio (in times) <i>Definition: Net debts/net worth</i> <i>{Net debts: Long term borrowings (including current maturities and gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances}</i>	0.20	0.23	0.41	0.20	0.41
11	Current ratio (in times) <i>Definition: Current assets/current liabilities</i>	1.40	1.39	1.47	1.40	1.47
12	Long term debt to working capital (in times) <i>Definition: Long term debt/working capital</i> <i>{Long term debt: Long term borrowings (including current maturities and gross of transaction costs)}</i> <i>{working capital: Current assets - current liabilities}</i>	0.65	0.66	1.78	0.65	1.78
13	Current liability ratio (in times) <i>Definition: Current liabilities/total liabilities</i>	0.68	0.69	0.53	0.68	0.53
14	Total debts to total assets (in times) <i>Definition: Total debts/total assets</i> <i>{Total debts: Long term borrowings (including current maturities and gross of transaction costs + short term borrowings)}</i>	0.12	0.13	0.23	0.12	0.23
15	Fixed assets coverage ratio (in times) <i>Definition: Total assets secured by a first pari-passu charge / indebtedness secured by or agreed to be secured by first charge over fixed assets (i.e. aggregate external borrowing)</i>	23.42	23.01	4.26	23.42	4.26

not annualised for the quarters

Figures for the year ended 31 March 2021 are not comparable as it represents only two months of operations of Life Science Ingredients business from 1 February 2021 to 31 March 2021 (refer note 10 for further details).

4. During the year ended 31 March 2021, the Composite Scheme of Arrangement ("Composite Scheme") for amalgamation of certain promoter controlled entities into Jubilant Pharmova Limited ("JPM"), the Demerged Company and demerger of the Life Science Ingredients business ("LSI business") into Jubilant Ingrevia Limited, the Company, was approved by Honourable National Company Law Tribunal ("NCLT"), Allahabad Bench vide its order dated 23 December 2020, formal order received on 6 January 2021. The said NCLT order was filed with the Registrar of Companies by JPM and the Company on 1 February 2021 thereby making the Composite Scheme effective. Accordingly, all assets and liabilities of the LSI business stands transferred and vested into the Company effective 1 February 2021, being the Appointed date as per the Scheme for demerger of the LSI business.
5. Pursuant to the Composite Scheme, the Life Science Ingredients business ("LSI business") of Jubilant Pharmova Limited got demerged into the Company with effect from 1 February 2021, accordingly, the standalone financial results of the Company for quarter and year ended 31 March 2021 includes only two months of operations of LSI business from 1 February 2021 to 31 March 2021. Therefore, in order to present the actual scale of operation of the LSI business, the management has presented, in addition to, the standalone financial results of the Company, the following financial information which has been derived/extracted from the financial results of the transferor company, Jubilant Pharmova Limited, to the extent related to LSI business, for respective periods presented, which has not been separately subjected to audit or review and has been presented as 'unaudited' supplementary information:

Particulars	(₹ in Lakhs)	
	Quarter Ended	Year Ended
	31 March	31 March
	(Unaudited)	(Unaudited)
	2021	2021
	(1 month)	(10 months)
i) Total revenue from operations	36586	270950
ii) Other income	109	3517
iii) Total income	36695	274467
iv) Total expenses	31620	246662
v) Profit before tax	5075	27805
vi) Tax expenses	1354	6153
vii) Net profit for the period	3721	21652

6. During the year ended 31 March 2022, the Company has entered into Share Purchase, Subscription and Shareholder's Agreement with AMP Energy C&I Private Limited and AMP Energy Green Fifteen Private Limited for acquisition of 26.60% stake of AMP Energy Green Fifteen Private Limited for the purpose of setting up a solar power plant with capacity of 15.5 MW for captive consumption of power and will be executed through power purchase agreement. Pursuant to that, the Company has made investment of ₹511 Lakhs in AMP Energy Green Fifteen Private Limited, representing investment in 511,500 Equity shares of ₹10 each and 46,035 Compulsorily Convertible Debenture of ₹1000 each. Further, during the quarter ended 31 March 2022, the Company has made additional investment of ₹71 Lakh presenting investment in 71,300 Equity shares of ₹10 each and 6,417 Compulsorily Convertible Debenture of ₹1000 each.
7. The Secured Rated Listed Redeemable Non-Convertible Debentures (NCDs) aggregating to ₹10000 lakhs outstanding as at 31 March 2022 are secured by a first pari-passu charge created by way of mortgage on certain immovable assets and hypothecation on entire movable property, plant and equipment, both present and future, of the Company. On 2 May 2022, CRISIL Limited has assigned the rating of "CRISIL AA/ Positive" to the said NCDs. The security cover thereof exceeds 100% of the outstanding principal amount of the said NCDs.

Details of due dates for payment of interest and repayment of principal of NCDs are as follows:

Particulars	Previous Due Date		Next Due Date	
	Principal	Interest	Principal	Interest
1000 -- 7.90% Non - Convertible Debentures of ₹ 10 Lakhs each	-	2 June 2021*	2 June 2023	2 June 2022

*Interest due on 2 June 2021 was paid on the due date

Further, the Finance Committee of the Board of Directors has, at its meeting held on 13 May 2022, approved early redemption and change in payment terms of NCDs of ₹ 1000 Lakhs which shall be redeemed subsequently.

8. The Board of Directors at their meeting held on 17 May 2022 have recommended a final dividend of ₹ 2.5 (250%) per equity share of ₹ 1 each amounting to ₹ 3982 Lakhs for the year ended 31 March 2022 subject to approval in Annual General Meeting. During the year ended 31 March 2022, the Company has already declared an interim dividend of ₹ 2.5 per equity share of ₹ 1 each and hence, the total dividend for the year ended 31 March 2022 is amounting to be ₹ 7964 Lakhs i.e. ₹ 5 (500%) per equity share of ₹ 1.
9. The Company is a "Large Corporate" as per criteria under SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated 26 November 2018. Necessary disclosure has been made to the stock exchanges, where securities of the Company are listed in this regard.
10. The segment earlier presented as "Life Science Chemicals" has been renamed as "Chemical Intermediates".
11. The figures for the quarter ended 31 March 2022, 31 December 2021 and year ended 31 March 2022 are not comparable with previous periods/year since the figures for quarter and year ended 31 March 2021 include results of demerged LSI business from Jubilant Pharmova Limited for two months, from the effective date of demerger i.e., 1 February 2021 till 31 March 2021.
12. The figures for the quarter ended 31 March 2022 and the corresponding quarter ended in the previous year, as reported in these standalone financial results, are the balancing figures between audited figures in respect of the full financial year and the published year to date figures until the end of third quarter of the relevant financial year. Also, for the year ended 31 March 2022, the figures until the end of the third quarter had only been reviewed and not subjected to audit and for the year ended 31 March 2021, figures until the end of the third quarter was audited.
13. Previous period figures have been regrouped /reclassified to conform to the current year's classification.
14. The above standalone audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 17 May 2022. The audit report of the Statutory Auditors is being filed with the BSE Limited and the National Stock Exchange of India Limited. For more details on standalone audited results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Ingrevia Limited



Rajesh Kumar Srivastava
CEO & Managing Director